Shopping Cart
Remove All
Your shopping cart is currently empty
Orilanolimab (Synonyms: SYNT001, SYNT 001, ALXN1830, ALXN 1830)
Catalog No. T78325 Copy Product Info
Purity: 95%
🥰Excellent
Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research.
Orilanolimab
Copy Product Info🥰Excellent
Catalog No. T78325
Synonyms SYNT001, SYNT 001, ALXN1830, ALXN 1830
Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research.
Orilanolimab
Cas No. 2066544-85-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $455 | - | In Stock | |
| 5 mg | $1,180 | - | In Stock | |
| 10 mg | $1,890 | - | In Stock | |
| 25 mg | $2,820 | - | In Stock | |
| 50 mg | $3,780 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.3% (SDS-PAGE); 97.0% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research. |
| In vitro | In primary CD11c+ APCs derived from B2MTG/TGFCGRTTG/TG Fcgrt-/- mice, Orilanolimab (10nM, 50nM, and 100nM，48 hours) suppressed IFN-γ secretion by OVA-specific CD8+ and CD4+ T cells [1]. |
| In vivo | In hFcRn-expressing mouse models, Orilanolimab (20 mg/kg, intravenous injection) significantly reduced the levels of human IgG and IgG ICs in plasma [1]. Orilanolimab (10, 30, 100 mg/kg, intravenous injection, once weekly) induced a dose-dependent and proposed reduction in total circulating IgG levels in cynomolgus monkeys [1]. |
| Synonyms | SYNT001, SYNT 001, ALXN1830, ALXN 1830 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | FcRn (FCGRT & B2M) |
| Molecular Weight | 144.02 kDa |
| Cas No. | 2066544-85-0 |
| Isotype | IgG1 |
| Storage | Store at low temperature | Store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Orilanolimab | purchase Orilanolimab | Orilanolimab cost | order Orilanolimab | Orilanolimab in vivo | Orilanolimab in vitro | Orilanolimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.